Eterna Therapeutics Inc (ERNA) - Net Assets
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has net assets worth $3.57 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.17 Million) and total liabilities ($2.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Eterna Therapeutics Inc (ERNA) total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.57 Million |
| % of Total Assets | 57.84% |
| Annual Growth Rate | -12.42% |
| 5-Year Change | -77.79% |
| 10-Year Change | -55.8% |
| Growth Volatility | 66.17 |
Eterna Therapeutics Inc - Net Assets Trend (2006–2024)
This chart illustrates how Eterna Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Eterna Therapeutics Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Eterna Therapeutics Inc (2006–2024)
The table below shows the annual net assets of Eterna Therapeutics Inc from 2006 to 2024. For live valuation and market cap data, see Eterna Therapeutics Inc (ERNA) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.70 Million | -23.82% |
| 2023-12-31 | $2.23 Million | -81.56% |
| 2022-12-31 | $12.11 Million | -52.53% |
| 2021-12-31 | $25.50 Million | +232.99% |
| 2020-12-31 | $7.66 Million | +50.44% |
| 2019-12-31 | $5.09 Million | -26.40% |
| 2018-12-31 | $6.92 Million | +24.95% |
| 2017-12-31 | $5.54 Million | +36.09% |
| 2016-12-31 | $4.07 Million | +5.72% |
| 2015-12-31 | $3.85 Million | -64.77% |
| 2014-12-31 | $10.92 Million | +18.71% |
| 2013-12-31 | $9.20 Million | +16.57% |
| 2012-12-31 | $7.89 Million | +24.31% |
| 2011-12-31 | $6.35 Million | -32.88% |
| 2010-12-31 | $9.46 Million | +0.46% |
| 2009-12-31 | $9.42 Million | +21.59% |
| 2008-12-31 | $7.75 Million | -50.24% |
| 2007-12-31 | $15.57 Million | -15.98% |
| 2006-12-31 | $18.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eterna Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 23153600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $257.00K | 15.11% |
| Other Components | $232.98 Million | 13696.65% |
| Total Equity | $1.70 Million | 100.00% |
Eterna Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Eterna Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Snipp Interactive Inc
V:SPN
|
$10.38 Million |
|
Palamina Corp
V:PA
|
$10.39 Million |
|
Saraswati Griya Lestari Tbk
JK:HOTL
|
$10.40 Million |
|
Norben Tea & Exports Limited
NSE:NORBTEAEXP
|
$10.40 Million |
|
MISSION GROUP PLC LS -10
F:M7K
|
$10.38 Million |
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
$10.38 Million |
|
Biovica International AB (publ)
ST:BIOVIC-B
|
$10.37 Million |
|
AEON Biopharma, Inc.
NYSE MKT:AEON
|
$10.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eterna Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,233,000 to 1,701,000, a change of -532,000 (-23.8%).
- Net loss of 44,539,000 reduced equity.
- Dividend payments of 16,000 reduced retained earnings.
- New share issuances of 1,137,000 increased equity.
- Other comprehensive income increased equity by 1,000.
- Other factors increased equity by 42,885,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-44.54 Million | -2618.4% |
| Dividends Paid | $16.00K | -0.94% |
| Share Issuances | $1.14 Million | +66.84% |
| Other Comprehensive Income | $1.00K | +0.06% |
| Other Changes | $42.88 Million | +2521.16% |
| Total Change | $- | -23.82% |
Book Value vs Market Value Analysis
This analysis compares Eterna Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 2.04x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $10243.79 | $3.81 | x |
| 2007-12-31 | $8606.34 | $3.81 | x |
| 2008-12-31 | $4282.16 | $3.81 | x |
| 2009-12-31 | $4855.64 | $3.81 | x |
| 2010-12-31 | $4719.95 | $3.81 | x |
| 2011-12-31 | $3153.87 | $3.81 | x |
| 2012-12-31 | $3430.19 | $3.81 | x |
| 2013-12-31 | $3836.20 | $3.81 | x |
| 2014-12-31 | $3741.95 | $3.81 | x |
| 2015-12-31 | $83.75 | $3.81 | x |
| 2016-12-31 | $85.51 | $3.81 | x |
| 2017-12-31 | $90.68 | $3.81 | x |
| 2018-12-31 | $102.93 | $3.81 | x |
| 2019-12-31 | $70.83 | $3.81 | x |
| 2020-12-31 | $66.30 | $3.81 | x |
| 2021-12-31 | $176.70 | $3.81 | x |
| 2022-12-31 | $59.52 | $3.81 | x |
| 2023-12-31 | $6.30 | $3.81 | x |
| 2024-12-31 | $1.87 | $3.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eterna Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2618.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7652.75%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 3.10x
- Recent ROE (-2618.40%) is below the historical average (-271.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -25.76% | -14.47% | 1.24x | 1.43x | $-6.63 Million |
| 2009 | -15.94% | -5.81% | 1.81x | 1.52x | $-2.44 Million |
| 2010 | -4.23% | -1.58% | 1.93x | 1.39x | $-1.35 Million |
| 2011 | -53.84% | -14.32% | 2.05x | 1.83x | $-4.05 Million |
| 2012 | -12.60% | -4.13% | 1.90x | 1.60x | $-1.78 Million |
| 2013 | -11.44% | -4.43% | 1.54x | 1.68x | $-1.97 Million |
| 2014 | -46.05% | -19.31% | 1.17x | 2.04x | $-6.12 Million |
| 2015 | -187.79% | -29.47% | 1.46x | 4.37x | $-7.61 Million |
| 2016 | -71.85% | -13.10% | 1.30x | 4.21x | $-3.33 Million |
| 2017 | -19.45% | -5.06% | 1.28x | 2.99x | $-1.63 Million |
| 2018 | -3.74% | -1.11% | 1.57x | 2.15x | $-950.70K |
| 2019 | -40.21% | -10.34% | 1.30x | 3.00x | $-2.56 Million |
| 2020 | 155.45% | 205.28% | 0.45x | 1.69x | $11.14 Million |
| 2021 | -480.49% | 0.00% | 0.00x | 1.24x | $-125.10 Million |
| 2022 | -203.01% | 0.00% | 0.00x | 1.84x | $-25.79 Million |
| 2023 | -970.35% | -31864.71% | 0.00x | 22.00x | $-21.89 Million |
| 2024 | -2618.40% | -7652.75% | 0.11x | 3.10x | $-44.71 Million |
Industry Comparison
This section compares Eterna Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eterna Therapeutics Inc (ERNA) | $3.57 Million | -25.76% | 0.73x | $10.38 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the tr… Read more